JAPAN TISSUE ENGINEERING CO., LTD. Japan Tissue Engineering Co., Ltd.
Equities
7774
JP3389610001
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 663 JPY | +0.45% |
|
+1.53% | +31.03% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Calendar
2024-04-29
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.03% | 170M | |
| +13.16% | 128B | |
| -8.76% | 10.65B | |
| +3.60% | 8.82B | |
| +19.75% | 7.19B | |
| +22.28% | 4.99B | |
| +7.55% | 3.4B | |
| -0.21% | 3.03B | |
| -4.80% | 2.14B | |
| -4.72% | 2B |
- Stock Market
- Equities
- 7774 Stock
- News Japan Tissue Engineering Co., Ltd.
- Japan Tissue Seeks Marketing Consent for Vitiligo Treatment Product
